scispace - formally typeset
G

Genlin Hu

Researcher at University of North Carolina at Chapel Hill

Publications -  5
Citations -  386

Genlin Hu is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Adeno-associated virus & Clotting factor. The author has an hindex of 5, co-authored 5 publications receiving 322 citations.

Papers
More filters
Journal ArticleDOI

Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.

TL;DR: The results may guide rational design of clinical trials using alternative AAV serotypes and suggest that younger patients who are given AAV gene therapy will benefit from the lower prevalence of NAbs.
Journal ArticleDOI

Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial

TL;DR: Preclinical studies demonstrate a safety:efficacy profile supporting an ongoing phase 1/2 human clinical trial of the scAAV8.FIXR338L vector and the role of empty capsids, as well as performing comprehensive dose–response, biodistribution, and safety evaluations in clinically relevant hemophilia models.
Journal ArticleDOI

IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia

TL;DR: Specific therapies to oppose inflammatory cytokines, including Interleukin 6 (IL‐6) receptor antagonists, have become important in the management of inflammatory arthritides.
Journal ArticleDOI

A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.

TL;DR: The study of cytokine profile changes during FVIII inhibitor development may be helpful to understand the mechanism of inhibitor development and to explore potential novel approaches that will minimize the risk.